Studies aimed at establishing which characteristics of patients with ulcerative proctitis could be predictive of the extension of inflammation have failed to provide conclusive results.
Dr Roberta Pica and colleagues undertook a study to evaluate the prognostic role of clinical and therapeutic parameters in patients with proctitis.
The researchers evaluated a total of 138 case records of patients with ulcerative proctitis.
The investigators considered the following parameters: gender; age at onset of disease; smoking habits; histologic severity of disease at onset; mean number of clinical relapses of disease per year; mean duration of oral and topical mesalazine treatment; and number of topical corticosteroid treatments per year.
|Mean duration of topical mesalazine treatment was longer in patients with extended proctitis|
|Inflammatory Bowel Diseases|
The research group excluded 28 patients from the analysis for different reasons.
During follow-up, the researchers found that inflammation spread proximally in 30% of patients.
In addition, the researchers found that patients with extended proctitis showed a significantly higher number of relapses and a shorter duration of oral mesalazine treatment than patients with nonprogressive proctitis.
Using multivariate analysis the research group also found that the mean duration of topical mesalazine treatment was longer in patients with extended proctitis.
Dr Pica concluded, "Ulcerative proctitis patients with more frequent relapses who need a longer duration of topical therapy are at higher risk of extension of the disease, while a more prolonged oral mesalazine treatment period protects against the proximal spread of rectal inflammation."